Literature DB >> 7639073

High acceptability and low morbidity of diagnostic lumbar puncture in elderly subjects of mixed cognitive status.

N J Hindley1, K A Jobst, E King, L Barnetson, A Smith, A M Haigh.   

Abstract

A total of 273 participants (186 with clinical dementia; 87 "normal" controls; mean age 72 years) in a prospective, longitudinal, dementia research study, underwent lumbar puncture (LP), where possible, on an annual basis. Reporting of symptoms after all LP's (n = 541) was 21.6%, the predominant complaints being mild localised back-pain (12.8%) and headache (10.7%). All symptoms were self-limiting. Analysis of headaches after all first LP's (n = 273) revealed an incidence of 14.2% with marked differences between subjects under 60 years of age (33%) and those over 60 years (10.1%), between subjects with "minimal" cerebral atrophy (19.5%) and those with "significant" atrophy (5.6%) and, to a lesser extent, between subjects with no or mild cognitive impairment (20.6%) and those with significant impairment (9.5%). Age under 60 years and lack of significant cerebral atrophy were shown to be independent predictors of headache. Acceptability of LP was high as demonstrated by agreement to a second procedure by 92.2% of eligible subjects. Our results show that LP can be successfully incorporated into research with the elderly.

Entities:  

Mesh:

Year:  1995        PMID: 7639073     DOI: 10.1111/j.1600-0404.1995.tb07029.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  [Diagnostic lumbar puncture performed in the outpatient setting of a memory clinic. Frequency and risk factors of post-lumbar puncture headache].

Authors:  J Popp; M Riad; K Freymann; F Jessen
Journal:  Nervenarzt       Date:  2007-05       Impact factor: 1.214

2.  Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease.

Authors:  Annika Ohrfelt; Ulf Andreasson; Adam Simon; Henrik Zetterberg; Ake Edman; William Potter; Daniel Holder; Viswanath Devanarayan; Jeffrey Seeburger; A David Smith; Kaj Blennow; Anders Wallin
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-01-14

3.  Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study.

Authors:  Jonathan H Williams; Gordon K Wilcock; Jeffrey Seeburger; Aimee Dallob; Omar Laterza; William Potter; A David Smith
Journal:  Alzheimers Res Ther       Date:  2011-02-17       Impact factor: 6.982

4.  Cerebrospinal fluid findings in geriatric patients from 2008 to 2011.

Authors:  M Djukic; D Schulz; H Schmidt; P Lange; R Nau
Journal:  Z Gerontol Geriatr       Date:  2013-06       Impact factor: 1.292

5.  High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.

Authors:  Ronald C Hendrickson; Anita Y H Lee; Qinghua Song; Andy Liaw; Matt Wiener; Cloud P Paweletz; Jeffrey L Seeburger; Jenny Li; Fanyu Meng; Ekaterina G Deyanova; Matthew T Mazur; Robert E Settlage; Xuemei Zhao; Katie Southwick; Yi Du; Dan Holder; Jeffrey R Sachs; Omar F Laterza; Aimee Dallob; Derek L Chappell; Karen Snyder; Vijay Modur; Elizabeth King; Catharine Joachim; Andrey Y Bondarenko; Mark Shearman; Keith A Soper; A David Smith; William Z Potter; Ken S Koblan; Alan B Sachs; Nathan A Yates
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

Review 6.  State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease.

Authors:  Harald Hampel; Leslie M Shaw; Paul Aisen; Christopher Chen; Alberto Lleó; Takeshi Iwatsubo; Atsushi Iwata; Masahito Yamada; Takeshi Ikeuchi; Jianping Jia; Huali Wang; Charlotte E Teunissen; Elaine Peskind; Kaj Blennow; Jeffrey Cummings; Andrea Vergallo
Journal:  Alzheimers Dement       Date:  2021-05-27       Impact factor: 16.655

7.  Schizophrenia genomics and proteomics: are we any closer to biomarker discovery?

Authors:  Shaheen E Lakhan; Alon Kramer
Journal:  Behav Brain Funct       Date:  2009-01-07       Impact factor: 3.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.